Life Sciences Venture Capital Monitor – Europe 05/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 05/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of May 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 3,963m
  • Top 5 Deals exceed EUR 110m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
  • Revival Healthcare Capital (United States) dominates the Top 5 Investors (by deal volume), followed by Gilde Healthcare Partners (Netherlands) and European Innovation Council Fund (Belgium)
  • Biotech received 45% of the total investment volume (-8% compare to the previous month)
  • Oncology dominates as the top indication in Biotechnology
  • YgEia3 closed a EUR 683m Series E financing round, increasing the funding volume for May 2023 significantly

To access the full report, please click here.

By Mathias KlozenbücherJohannes Link and Marco Buonafede-Bennardo.